IL317183A - Combinations of rxfp1 modulators and sglt2 inhibitors - Google Patents

Combinations of rxfp1 modulators and sglt2 inhibitors

Info

Publication number
IL317183A
IL317183A IL317183A IL31718324A IL317183A IL 317183 A IL317183 A IL 317183A IL 317183 A IL317183 A IL 317183A IL 31718324 A IL31718324 A IL 31718324A IL 317183 A IL317183 A IL 317183A
Authority
IL
Israel
Prior art keywords
rxfp1
modulators
combinations
sglt2 inhibitors
sglt2
Prior art date
Application number
IL317183A
Other languages
Hebrew (he)
Inventor
Anders Gabrielsen
Daniel Tor Pettersen
Kathleen Marie Connolly
Marcin Ufnal
Original Assignee
Astrazeneca Ab
Anders Gabrielsen
Daniel Tor Pettersen
Kathleen Marie Connolly
Marcin Ufnal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Anders Gabrielsen, Daniel Tor Pettersen, Kathleen Marie Connolly, Marcin Ufnal filed Critical Astrazeneca Ab
Publication of IL317183A publication Critical patent/IL317183A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL317183A 2022-06-07 2023-06-06 Combinations of rxfp1 modulators and sglt2 inhibitors IL317183A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263365969P 2022-06-07 2022-06-07
PCT/EP2023/065046 WO2023237512A1 (en) 2022-06-07 2023-06-06 Combinations of rxfp1 modulators and sglt2 inhibitors

Publications (1)

Publication Number Publication Date
IL317183A true IL317183A (en) 2025-01-01

Family

ID=86861850

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317183A IL317183A (en) 2022-06-07 2023-06-06 Combinations of rxfp1 modulators and sglt2 inhibitors

Country Status (11)

Country Link
US (1) US20260069559A1 (en)
EP (1) EP4536207A1 (en)
JP (1) JP2025519439A (en)
KR (1) KR20250020503A (en)
CN (1) CN119325376A (en)
AU (1) AU2023284027A1 (en)
CA (1) CA3257184A1 (en)
IL (1) IL317183A (en)
MX (1) MX2024015074A (en)
TW (1) TW202415364A (en)
WO (1) WO2023237512A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260116187A (en) * 2023-11-17 2026-07-28 일라이 릴리 앤드 캄파니 RXFP1 receptor agonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
AU2021395353B2 (en) * 2020-12-08 2024-08-29 Astrazeneca Ab 4-(2-fluoro-4-methoxy-5-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as rxfp1 modulators for the treatment of heart failure

Also Published As

Publication number Publication date
KR20250020503A (en) 2025-02-11
JP2025519439A (en) 2025-06-26
CA3257184A1 (en) 2023-12-14
US20260069559A1 (en) 2026-03-12
TW202415364A (en) 2024-04-16
CN119325376A (en) 2025-01-17
AU2023284027A1 (en) 2025-01-23
WO2023237512A1 (en) 2023-12-14
EP4536207A1 (en) 2025-04-16
MX2024015074A (en) 2025-01-09

Similar Documents

Publication Publication Date Title
EP4093385A4 (en) Pgdh inhibitors and methods of making and using
EP4143196A4 (en) PI3K-a INHIBITORS AND METHODS OF USE THEREOF
IL321357A (en) Inhibitors of kif18a and uses thereof
IL317543A (en) Kinase modulators and methods of use thereof
CA3264917A1 (en) Inhibitors of kif18a and uses thereof
IL312466A (en) Pi3k-alpha inhibitors and methods of making and using the same
EP4341254A4 (en) Inhibitors and degraders of pip4k protein
EP4329735A4 (en) Kcnt1 inhibitors and methods of use
IL317288A (en) Inhibitors of expression and/or function
EP4025197A4 (en) Inhibitors of sglt and uses thereof
IL321255A (en) Adar1 inhibitors and methods of using the same
HK40127096A (en) Combinations of rxfp1 modulators and sglt2 inhibitors
EP4119164A4 (en) Anti-coronavirus effect and application of pi4k inhibitor
AU2024397820A1 (en) Vps34 inhibitors and methods of use thereof
IL325863A (en) Inhibitors of expression and/or function
HK40107819A (en) Wdr5 inhibitors and modulators
GB202208124D0 (en) Inhibitors of expression and/or function
GB202208122D0 (en) Inhibitors of expression and/or function
HK40101141A (en) Gpr52 modulators and methods of use
CA3275344A1 (en) Adar1 inhibitors and methods of using the same
HK40082392A (en) Gpr52 modulators and methods of use
CA3299172A1 (en) Inhibitors of expression and/or function
CA3293419A1 (en) Inhibitors of expression and/or function
HK40108854A (en) Kcnt1 inhibitors and methods of use
HK40120757A (en) T-type calcium channel modulators comprising an azaspiroheptane core and methods of use thereof